• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[经淋巴管多药化疗后膀胱癌的病理形态变化]

[Pathomorphosis of bladder cancer after endolymphatic polychemotherapy].

作者信息

Danil'chenko S A, Shlopov V G, Serniak P S, Geev Iu V

出版信息

Arkh Patol. 1986;48(7):31-5.

PMID:3092786
Abstract

Clinical and morphological features of urinary bladder transitional carcinoma pathomorphosis after regional endolymphic polychemotherapy were studied to estimate the criteria of treatment efficiency and prognosis. Quantitative assessment of chemosensitive and chemoresistant tumours is given. The degree of cataplasia, growth character, the amount of stroma, blood supply and intensity of mononuclear infiltration predetermine the stage of pathomorphosis, efficiency of bladder cancer treatment. Studies of stromal immunomorphology, features of blood supply, mechanisms of neoplastic angiogenesis provide better understanding of biological nature of tumours, improve prognosis and choice of treatment.

摘要

研究了膀胱移行癌区域内淋巴多药化疗后病理形态变化的临床和形态学特征,以评估治疗效果和预后标准。给出了对化疗敏感和耐药肿瘤的定量评估。化生程度、生长特征、间质数量、血液供应和单核浸润强度决定了病理形态变化阶段和膀胱癌治疗效果。对间质免疫形态学、血液供应特征、肿瘤血管生成机制的研究有助于更好地理解肿瘤的生物学特性,改善预后和治疗选择。

相似文献

1
[Pathomorphosis of bladder cancer after endolymphatic polychemotherapy].[经淋巴管多药化疗后膀胱癌的病理形态变化]
Arkh Patol. 1986;48(7):31-5.
2
[Intra-arterial chemotherapy of patients in the late stages of bladder cancer].[膀胱癌晚期患者的动脉内化疗]
Urol Nefrol (Mosk). 1985 Mar-Apr(2):19-23.
3
[Retrospective evaluation of the efficacy of regional endolymphatic polychemotherapy in kidney cancer depending on the histologic structure of the tumor].[根据肿瘤组织学结构对区域内淋巴多药化疗在肾癌中的疗效进行回顾性评估]
Urol Nefrol (Mosk). 1989 May-Jun(3):40-2.
4
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.1998年至2003年III期膀胱癌围手术期化疗的低发生率:来自国家癌症数据库的报告。
J Urol. 2007 Aug;178(2):451-4. doi: 10.1016/j.juro.2007.03.101. Epub 2007 Jun 11.
5
Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.浸润性尿路上皮癌的辅助化疗:甲氨蝶呤、长春新碱、顺铂、环磷酰胺、阿霉素和博来霉素(MVP-CAB)方案的经验:初步报告
Jpn J Clin Oncol. 1993 Oct;23(5):291-8.
6
Induction chemotherapy with cisplatin and cyclophosphamide and maintenance chemotherapy with doxorubicin and 5-FU in advanced urinary bladder tumors.
Cancer Treat Rep. 1983 Feb;67(2):200-1.
7
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.欧洲癌症研究与治疗组织(EORTC)22971 二期试验的结果,该试验评估了肌肉浸润性膀胱移行细胞癌患者联合加速外照射放疗以及 5-氟尿嘧啶和顺铂化疗的疗效。
Acta Oncol. 2008;47(5):937-40. doi: 10.1080/02841860801888799.
8
Current topics in the pathology of bladder cancer.膀胱癌病理学的当前主题
Pathol Annu. 1983;18 Pt 1:1-25.
9
Chemotherapy of metastatic bladder cancer.
Cancer. 1980 Apr 15;45(7 Suppl):1879-88.
10
Developing innovative strategies for advanced transitional cell carcinoma of the bladder.为晚期膀胱移行细胞癌开发创新策略。
Expert Rev Anticancer Ther. 2006 Jan;6(1):83-92. doi: 10.1586/14737140.6.1.83.